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Introduction
According to World Health Organization’s (WHO) 
statistics, common cancers are one of the most prevalent 
causes of mortality worldwide with 8.2 million deaths 
in 2012, and this trend has not changed in recent years. 
Viral infections contribute to 15-20% of all human 
cancers, whereby several viruses play significant roles 
in the multistage development of malignant cancers. 
The correlation between a given virus and its associated 
cancer ranges from 15-100% (McLaughlin-Drubin et al., 
2008). Cancer became a priority public health challenge 
in Kazakhstan as a Member State of the WHO. Cervical 
cancer is the second most common cancer among women 
all over the world, with more than 85% of the cases 
occurring in developing countries (Senapathy et al., 2011). 
Almost 90% of cervical cancer cases are caused by HPV 
infection (Schiffman et al., 2009). HPVs are a large group 
of viruses, which consists of more than 180 different 
types, among which 15 have high oncogenic properties 
(Bernard et al., 2010). HPV infection can lead to various 
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types of diseases from benign lesions to cancer. In 2007, 
an International Agency for Research on Cancer (IARC) 
working group classified 21 HPV types (HPV 6, 11, 16, 
18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 
73 and 82) as the most prevalent for their association with 
cervical cancer (IARC, Monographs on the Evaluation of 
Carcinogenic Risks to Humans, Volume 90, 2007).
However, very scarce and scattered information 
are available about HPV infection epidemiology in 
Kazakhstan. Therefore, the purpose of this review article 
is to summarize the existing data, identify the direction for 
the future research, and enhance public awareness about 
HPV infection and HPV-related diseases in Kazakhstan 
and the Central Asian region. 
Materials and Methods
Systematic literature search was performed by a 
detailed survey of issued peer reviewed articles on HPV 
infection and cervical cancer in Kazakhstan up to July 
31, 2017 from the following databases: PubMed, Web of 
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Science and Google Scholar. The search was done without 
language limitation, during June-July 2017. The key 
words “HPV”, “Kazakhstan”, “genotype”, “vaccination”, 
“screening” and “cervical cancer” were used for the 
search. This resulted in 229 relevant articles. Abstracts 
of all the 229 articles were read to determine relevance to 
this review. Inclusion criteria; articles that were included 
in this review mentioned at least one specific HPV-related 
test that was being evaluated. Since we have included the 
epidemiologic data from international journals and local 
non-indexed medical journals, the following inclusion 
criteria were applied: general population data, cytology 
results available, and use of polymerase chain reaction 
and/or Hybrid Capture® 2, Digene Corp., USA for HPV 
detection. Exclusion criteria; articles that were published 
before 1990, and articles describing contribution of other 
infections sexual transmitted infections to cervical cancer 
morbidity were not included. Application of inclusion/
exclusion criteria resulted in 36 relevant articles on the 
topic of the review. Of the articles reviewed, 3 were 
additionally included in this report from the local non-
indexed journals, published in Russian and translated into 
English with the links provided in the list of references. 
This search strategy resulted in 39 total articles that 
are included in this analysis. Since published data in 
international indexed medical journals are very limited 
and scarce, additional data have been obtained from the 
Catalan Institute of Oncology (ICO) HPV Information 
Centre report – 2017 and International Agency for 
Research on Cancer Monographs on the Evaluation of 
Carcinogenic Risks to Humans. 
In general, the information available on HPV 
prevalence in Kazakhstan is very tenuous and it became 
obvious that further research studies need to be done 
within this scientific field. 
Results
Epidemiology of HPV infection in Kazakhstan - prevalence 
and type distribution 
There have been many studies worldwide on the 
epidemiology of HPV infection, and oncogenic properties 
due to different HPV genotypes (Munoz et al., 2004; 
Clifford et al., 2003; Smith et al., 2007). However limited 
data are available on HPV prevalence, incidence and 
genotype specific dissemination in Central Asia, Africa 
and Eastern Europe. According to the report of HPV 
Information Centre (2017), no data on the epidemiology 
of HPV infection are available in Kazakhstan. There are 
only a few articles on the epidemiology of HPV infection 
in Kazakhstan published in international peer reviewed 
journals and several articles in local medical journals. 
The search in the international journals on HPV 
epidemiology has allowed us to find the largest study of 
HPV prevalence (1,661 samples), which was done in the 
Western part of Kazakhstan (Bekmukhambetov et al., 
2016). The study on HPV prevalence and distribution was 
performed by analyzing retrospective data, obtained from 
Russian-Kazakh joint venture “Olympus” laboratories 
network” accredited by International Organization for 
Standardization (ISO 15189). The laboratory network 
used AmpliSens® Real-Time PCR kits and the PCR 
analyzer Rotor-Gene 6000 (Germany) for HPV testing, 
which detected 12 different HPV genotypes (16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, and 59) (Bekmukhambetov 
et al., 2016).
This study identified the five most common HPV 
types, which were 16 (10.7%), 39 (5.83%), 51 (5.27%), 31 
(4.85%) and 56 (4.58%) (Bekmukhambetov et al., 2016). 
Type 16 was found as dominating and widely spread 
in the Western region of the country. The study did not 
assess the different type of the cervical lesion using the 
Papanicolaou test (Pap test).
Another article, published in the local non-reviewed 
journal presented the results of 595 patients’ HPV PCR 
genotyping in the Western region (Junerbayeva et al., 
2015). PCR genotyping was done in the “Olympus” 
laboratories network” using AmpliSens® Real-Time 
PCR proceeded with the use of analyzer Rotor-Gene 6000 
(Germany) to determine 12 most oncogenic types. This 
study demonstrated that 55.8% of the surveyed women 
were infected with HPV. The most prevalent types detected 
were HPV 16 (27.7%), HPV 31 (13.6%), HPV 52 (9.9%), 
HPV 18 (9.6%) and HPV 33 (3.6 %) (Junerbayeva et al., 
2015). 
Yet another study on HPV prevalence was performed 
by us in the Central part of Kazakhstan and included 140 
samples (Niyazmetova et al., 2017). HPV genotyping of 
12 different types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58 and 59) was done in the Republican Diagnostic Center 
(RDC), University Medical Center (UMC) with real time 
multiplex PCR methodology, using the specific PCR kit. 
The laboratory method used was based on simultaneous 
real-time multiplex PCR of HPV-specific DNA fragments 
and a noncompetitive internal control. The real time 
PCR instrumentation used for the assay was the CFX 96 
Real -Time PCR (BIO-RAD). The findings demonstrated 
that 43.6% of the patients were HPV positive. The most 
prevalent types detected were HPV 16 (18.4%) and HPV 
18 (9.22%), followed by HPV types 33, 51 and 52 (nearly 
5% each) (Niyazmetova et al., 2017). HPV types 59, 
39, 31, 45, and 58 were found in at least 2% of the total 
amount of samples, while only about 1% or less of positive 
samples had HPV types 35 and 56. The study, along 
with PCR HPV genotyping, performed the microscopic 
examination of Pap smear samples using standard UMC 
hospital protocols to evaluate the grade of HPV caused 
cervical lesions.
From the research data summarized above, we know 
that HPV testing is available on a self-payment basis in 
large cities of Kazakhstan. However there is no published 
statistical information on HPV epidemiology from the 
rural areas of the state. The reason may be due to absence 
of the specialized equipment for testing HPV and/or low 
awareness of the population and medical staff about the 
importance of HPV detection and Pap smear screening in 
cervical cancer prevention. 
Epidemiology of HPV-related cancers in Kazakhstan
Head and neck cancers
Human papillomaviruses infect basal skin and mucosal 
cells. There is an international consensus that “high-risk” 
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cancer is rare in the general population with an average 
worldwide incidence of 1 per 100,000. Globally, there is 
an estimated 27,000 new cases of anal cancer every year 
(de Martel et al., 2012). Women have higher incidences of 
anal cancer than men. Incidence is particularly high among 
populations of women with history of cervical or vulvar 
cancer, people practicing anal sexual intercourse, and in 
immunosuppressed populations. The type of anal cancer 
is mostly squamous cell carcinoma, adenocarcinomas, or 
basaloid and cloacogenic carcinomas. 
The annual burden of penile cancer has been estimated 
to be 22,000 cases worldwide with incidence rates strongly 
correlating with those of cervical cancer (de Martel et 
al., 2012). Incidence rates are higher in less developed 
countries than in more developed countries, accounting for 
up to 10% of male cancers in some parts of Africa, South 
America and Asia. Cancers of the penis are primarily of 
squamous cell carcinomas type (95%) (Bruni et al., 2017). 
Approximately 60-100% of precancerous penile lesions 
are HPV DNA positive.
Cancer of the vagina and vulva are rare cancers, 
representing 2-4% of all gynecologic cancers (de Martel 
et al., 2012). Similar to cervical cancer, the majority 
of vulvar and vaginal cancer cases (68%) occur in less 
developed countries and present slightly higher incidence 
in urban compared to rural regions (Makimbetov and 
Shalbaeva, 2014). Most vaginal cancers are squamous cell 
carcinoma (90%) generally attributable to HPV. Vulvar 
cancer has two different histological types: the warty and 
keratinizing types (IARC, Monographs on the Evaluation 
of Carcinogenic Risks to Humans, Volume 100(B), 2012). 
Cervical cancer 
Cancer of the cervix uteri is the fourth most common 
cancer among women worldwide, with an estimated 
527,624 new cases and 265,672 deaths in 2012 (Globocan). 
The majority of cases are squamous cell carcinoma 
followed by adenocarcinomas. (Wright et al., 2006; 
IARC, Monographs on the Evaluation of Carcinogenic 
Risks to Humans, Volume 90, 2007; Giuliano et al., 
2008; Bruni et al., 2017). In spite of effective screening 
methods, cervical cancer continues to be a major public 
health problem (Arbyn et al., 2008; Ferlay et al., 2015). 
Statistical data in Central Asia are limited (Bruni et al., 
2017), although a slight increase has been noted over 
the last ten years in Kazakhstan, especially among the 
middle-aged groups (Igissinov et al., 2011). The incidence 
rates of cervical cancer in many countries of Central Asia 
are quit high (ranging from 9.9 per 100,000 women in 
Tajikistan to 29.4 per 100,000 in Kazakhstan) (Bray et 
al., 2013), compared to Europe (ranging from 4.0 per 
100,000 in Finland and 7.0 per 100,000 in Germany) 
(Curado et al., 2007). Approximately 25,700 women are 
diagnosed with cervical cancer and 12,700 die from this 
disease annually in Central Asian countries (Bray et al., 
2013). The mortality rates - range from 4.9 per 100,000 
women in Tajikistan to 11.2 per 100,000 in Kyrgyzstan 
(Bray et al., 2013; Bruni et al., 2017). The indicators are 
higher than in Western European countries (incidence rates 
ranging from 2.1 per 100,000 women in Malta to 12.2 per 
100,000 in Portugal; mortality rates ranging from 0.8 per 
genotypes can lead to cervical cancer and are associated 
with other mucosal anogenital and head and neck cancers 
(IARC, Monographs on the Evaluation of Carcinogenic 
Risks to Humans, Volume 90, 2007). Three cancer groups 
have been linked to HPV infection: the cervix, other 
anogenital tract (vulvar, vaginal, anal, and penile), and 
head and neck (oropharynx, oral cavity, and larynx). 
Most HPV infections are asymptomatic whereby more 
than 90% of detected infections are cleared within 12-24 
month without causing any lesions (Moscicki et al., 2006). 
Progression to cancer depends on the degree of immune 
protection of each particular person. Current evidence 
suggests that HPV16 is associated with tonsil cancer 
(including Waldeyer ring cancer), base of tongue cancer 
and other oropharyngeal cancer sites (IARC, Monographs 
on the Evaluation of Carcinogenic Risks to Humans, 
Volume 100 (B), 2012).
Very limited data are available on the epidemiology 
of HPV-related cancers in Kazakhstan (Igissinov et 
al., 2011; Igissinov et al., 2012; Igissinov et al., 2013; 
Zatonskikh et al., 2016). For example, cancer of the oral 
cavity and oropharynx is the most common form of head 
and neck tumors (Adilbayev et al., 2016). However, in 
Kazakhstan, only one study on the general prevalence of 
HPV-associated head and neck cancer has been conducted 
and published by Adilbayev (2016) in the international 
peer-reviewed journal. Some studies were done on HPV 
related diseases in Kazakh ethnic group among China 
population (Lu et al., 2008; Cui et al., 2014), but these 
did not contribute to the Kazakhstani statistical database. 
When discussing particular HPV-related head and 
neck cancers, according to available research data, the 
most studied in Kazakhstan is laryngeal cancer (Igissinov 
et al., 2013; Zatonskikh et al., 2016). Epidemiological 
study of laryngeal cancer in Kazakhstan shows that 
the dynamics of incidence are decreasing. The actual 
decline of the laryngeal cancer cases is significant and 
is equal to 36.9% for the entire population (Zatonskikh 
et al., 2016). However, the worldwide epidemiological 
observations define that with the population growth and 
changing in its age structure, the number of patients with 
malignant tumors of the larynx should increase. As the 
author Zatonskikh (2016) explained these controversial 
data with the demographic and socioeconomic changes 
in the recent 15 years, as one of the most important 
epidemiological factors that influenced the occurrence of 
cancers in the Kazakhstani population (Igissinov et al., 
2013; Zatonskikh et al., 2016). Crude incidence rate of 
oral cavity and pharynx malignant neoplasms tended to 
increase from 1999 to 2011 among the total population 
(Igissinov et al., 2011). According to the International 
HPV Centre report, crude incidence rate of pharyngeal 
cancer in 2017 (excluding nasopharynx) was 4.4 for male 
and 1.5 for female, with crude mortality rate of 3.0 and 
1.0 relatively (Bruni et al., 2017). 
Anogenital cancers other than the cervix
According to the recent HPV center report, no 
data were available on the epidemiology of anogenital 
cancers other than the cervix (anal, vulvar, vaginal and 
penile cancers) in Kazakhstan (Bruni et al., 2017). Anal 
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100,000 women in Iceland to 3.6 per 100,000 in Portugal) 
(Ferlay et al., 2010). 
In Kazakhstan, at least one woman in 50 develops 
cervical cancer before the age of 75 (Bray et al., 2013). 
Cervical cancer is the 1st most common female cancer in 
women aged 15 to 44 years in Kazakhstan, and ranks as 
the 2nd leading cause of female cancer with the incidence 
about 2,789 new cervical cancer cases diagnosed annually 
(estimations for 2012) (Bruni et al., 2017). Cervical 
cancer is the 4th leading cause of female cancer deaths 
in Kazakhstan with of about 982 cervical cancer deaths 
annually (Bruni et al., 2017).
Epidemiologic investigation on cervical cancer by 
Igissinov (2012) shows that the average age of cervical 
cancer patients in Kazakhstan is 53.5±0.7 years, with 
the average incidence rate of 14.5 per 100,000 women 
and mortality rate of 8.0. The incidence among women 
of reproductive age is 2.2 times lower than those figures 
for postmenopausal age (Igissinov et al., 2012). There 
is significant geographical difference in cervical cancer 
incidence and mortality in Kazakhstan. The incidence 
among women of reproductive age was found to be 
the highest in Northern part of the country at 16.3 per 
100.000 and the lowest on the West of the country with 
12.7 per 100.000 populations. The incidence among 
women of postmenopausal age is 1.7 times higher than 
in reproductive age (27.9 and 34.4 respectively). The 
mortality rate ranges from 7.1 to 12.6 per 100.000 in the 
same parts of the country respectively (Igissinov et al., 
2012). 
Having the significant high incidence and mortality 
from cervical cancer makes the screening program very 
important. Enhancing public awareness of underlying 
causal factors is a high priority for developing an 
appropriate cancer control and prevention program.
Cervical cancer screening in Kazakhstan
Cervical cancer screening strategies are different 
between countries. Some countries have population-based 
programs, whereby women in the target population are 
individually identified and invited to attend screening. 
In opportunistic screening, invitations depend on the 
individual’s decision or on encounters with health-care 
providers. The most frequent method for cervical cancer 
screening is cytology (Bruni et al., 2017). There is also 
discrepancy in the frequency of the screening tests. 
In developed countries like England and the USA, 
screening is scheduled for every 3 years for women in 
their reproductive age (Chorley et al., 2017; Smith et al., 
2017), while in developing countries (India, Peru, Kenia) 
the screening is scheduled every 5 years or even rarer 
(Gupta et al., 2017). 
Results of the population-based survey of adults aged 
50–70 in England suggest that although awareness of the 
purpose of early detection screening is high, awareness 
that screening can prevent cancer is low across all 
demographic groups. 
Cervical cancer screening in Kazakhstan was mainly 
opportunistic till 2005 and was characterized by cytology 
testing, using Romanowsky staining. Starting from 
2005 cytological screening of cervical cancer has been 
conducted, and the government covers expenses on 
cytology screening, biopsy and treatment (Nikulshina 
et al., 2016). 
Screening program covered different age groups in 
different years; in 2005 it covered the age group 30 to 34 
years, whereas in 2006 and 2007 the program covered the 
18 to 49 years age group. Since 2008, the State Cancer 
Screening Program has been adopted, and target groups 
of women aged 30 to 60 years have been identified. 
Screening for the program is conducted for women every 
5 years.
The cervical sample material for the study should 
be obtained from the cervix using Cervix-Brush. The 
method of staining preparation in 2006, 2007 was 
performed according to the Romanowsky method. 
Starting from 2008, 60% of all studies were prepared 
using the Papanicolaou method and 40% according to 
Romanowsky. Since 2009, 100% of all screening studies 
are stained by Papanicolaou. According to the HPV 
Information Center database, cervical cancer screening 
program covered 80% women aged 25-64 (Bruni et al., 
2017). The Pap test combined with a regular screening 
program, has been shown to reduce mortality from 
cervical cancer by more than 70% (Arbyn et al., 2010).
Starting from September 2013 liquid based cytology 
screening was implemented and applied into the daily 
screening practice (Kairbayev et al., 2009). The method 
of liquid based cytology (LC) was first developed to 
improve the effectiveness of the traditional Pap test, as 
well as to improve the quality of specimens from the 
cervix. A special feature of the LC method is the presence 
of a liquid medium, which is designed to preserve the 
cellular material obtained from the cervix. Subsequently, 
the cell suspension is processed to obtain a more uniform, 
thin layer of cervical cells with less cell debris on the 
slide. The goal of this process is to potentially reduce 
the incidence of two major deficiencies that occur in the 
traditional cytological study; (1) obtaining a relatively 
small and potentially unrepresentative cell sample (in 
fact, only about 20% of the cells obtained are transferred 
to glass), and (2) the effects of other types of material, 
including mucus, blood and other cells (not from the 
cervix) (Abulafia et al., 2003).
In general, the screening program in Kazakhstan is 
improving. Advantages of the liquid based cytology in 
terms of detection of the early stages lesion are confirmed. 
Accurate cervical screening practice will result in 
significantly reducing cervical cancer mortality. 
HPV vaccination in Kazakhstan
HPV vaccines are very effective at preventing 
infection and disease related to the vaccine-specific 
genotypes in women with no evidence of past or current 
HPV infection (Cutts et al., 2007). Vaccination program 
have been very successfully implemented in many 
countries all over the world [Mesher et al., 2013; Osborne 
et al., 2015; Tanaka et al., 2017). For example, the most 
recent study from Japan demonstrated results from women 
aged 20-24 years who received HPV vaccination, and had 
significantly lower rates of abnormal cervical cytology 
results when compared to those who did not receive the 
Asian Pacific Journal of Cancer Prevention, Vol 19 1179
DOI:10.22034/APJCP.2018.19.5.1175
Epidemiology of HPV in Kazakhstan 
vaccine (Tanaka et al., 2017). 
In Kazakhstan, a vaccination program supported by 
the government was started as a pilot project in the years 
2011-2013. During this time, the prophylactic vaccination 
of adolescent girls ages 10-13 years was performed, but 
later found to be improperly implemented, and now 
almost fully discontinued. Currently there is no the state 
program for HPV vaccination in Kazakhstan. However, 
adult women have the opportunity to be vaccinated in 
private hospitals or vaccination outpatient departments. 
Cost-effectiveness study, which was done in 
Kazakhstan by Nurgozhin (2013) shows benefits from 
HPV vaccination (Nurgozhin et al., 2013); however in 
spite of this knowledge, the HPV immunization program 
has not yet been implemented at the national level that 
would cover the entire population of Kazakhstan.
Discussion
As reported in different studies, the prevalence of 
HPV infection in Kazakhstan ranges from 43.8% to 
55.8%, with the most prevalent types of HPV being 16 
(10.7-27.7%), 18 (9.2-9.6%), 51 (5%), and 33 (3.6-5%). 
However the scenario with epidemiology of HPV related 
cancers in Kazakhstan is not very clear. Accordingly, one 
study reported a decline of laryngeal cancer observed 
during the recent years, cited to be equal to 36.9% of the 
whole population. Crude incidence rate of oral cavity 
and pharynx malignant neoplasms tended to increase 
from 1999 to 2011 within the total population. Statistical 
data on anogenital cancers in Kazakhstan however are 
not available. 
Cervical cancer is the 2nd leading cause of female 
cancer and the 4th leading cause of female cancer deaths 
in Kazakhstan. The incidence of cervical cancer is about 
3000 new cervical cancer cases, with about 1,000 cervical 
cancer deaths each year. There is an inequality of cervical 
cancer incidence and mortality in the different regions of 
the country. The incidence was found to be the highest in 
Northern part of the country at 16.3 % and the lowest on 
the Western part of the country at 12.7% with mortality 
rate that ranges from 7.1 to 12.6 % respectively. In 
comparison with the developed countries of Europe and 
North America, where the age-standardized incidence 
of cervical cancer is less than 9 % (Curado et al., 2007), 
Kazakhstani statistical data reveals depressing indicators. 
This imbalance is attributed mainly to the effective and 
successful implementation of organized cervical cancer 
screening programs in developed countries leading to early 
detection and appropriate management of precancerous 
lesions (Peto et al., 2004). 
High incidence of cervical cancer with significant 
mortality is an evidence of HPV infection abundance with 
absence of the HPV screening and low public awareness 
of the problem. The educational health promotion projects 
for the population should be provided to enhance the 
knowledge and conversance of this public health problem. 
From the review given here, it is clear that the HPV 
screening along with the vaccination program should be 
implemented at the governmental level in Kazakhstan. 
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